Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. (IRWD) is a small-cap pharmaceutical company focused on developing and commercialising treatments primarily for gastrointestinal disorders. With a market capitalisation around $253 million, the company’s income mix has historically included partnership and licensing revenues alongside its own R&D efforts. Investors should note Ironwood’s value is driven by pipeline progress, regulatory milestones and the performance of any marketed assets under partners, which can create lumpy revenue and share-price volatility. Key considerations include development and approval risk, competition from larger pharma players, and the company’s cash position and funding needs. For those assessing IRWD, look for clarity on upcoming clinical readouts, updates to partnership terms or royalty streams, and management’s plans for capital allocation. This is general educational information and not personalised investment advice; losses are possible and past performance is not a guide to the future.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Ironwood Pharmaceuticals' stock with a target price of $4.88, indicating possible growth.
Financial Health
Ironwood Pharmaceuticals is performing well with solid revenue, profits, and cash generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IRWD
The Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: August 15, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Partnership Revenues
Ironwood’s revenue can depend on licensing and partner payments, which provide upside but may be uneven; investors should watch partner performance and contract terms.
Pipeline Catalysts
Clinical readouts and regulatory milestones can move the share price significantly, though outcomes are uncertain and setbacks are possible.
Small-cap Considerations
With a modest market capitalisation, IRWD can be more volatile and less liquid than larger peers; suitable for investors willing to accept higher risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
